INHIBITOR Therapeutics Overview
- Year Founded
-
1992

- Status
-
Public
- Employees
-
6

- Stock Symbol
-
INTI

- Investments
-
1
- Share Price
-
$0.11
- (As of Friday Closing)
INHIBITOR Therapeutics General Information
Description
Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and commercializing therapies for patients with cancer and non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.
Contact Information
Website
www.inhibitortx.com
Formerly Known As
Hedgepath Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Discovery Tools (Healthcare)
Drug Discovery
Stock Exchange
PINX
Primary Office
- 324 South Hyde Park Avenue
- Suite 350
- Tampa, FL 33606
- United States
+1 (813) 000-0000
INHIBITOR Therapeutics Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.11 | $0.09 | $0.01 - $0.30 | $18.6M | 172M | 28K | $0.02 |
INHIBITOR Therapeutics Financials Summary
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
---|---|---|---|---|
EV | (812) | 41,534 | 60,573 | 17,024 |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | 10,287 | 12,185 | (284) | (1,059) |
Net Income | 10,502 | 12,106 | (299) | (1,058) |
Total Assets | 9,608 | 11,975 | 59 | 132 |
Total Debt | 0 | 411 | 231 | 97 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
INHIBITOR Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
INHIBITOR Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and commercializing therapies f
Pharmaceuticals
Tampa, FL
6
As of 2022
0000
000000000
0000
INHIBITOR Therapeutics Competitors (70)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Emmaus Life Sciences | Formerly VC-backed | Torrance, CA | 00 | 000.00 | 000000000 - | 000.00 |
0000000 0000000000 | Formerly VC-backed | Dallas, TX | 00 | 00000 | 000000&0 | 00000 |
0000000 0000000000 | Formerly VC-backed | Newark, CA | 00 | 00000 | 00000000 | 00000 |
00000000 | Formerly VC-backed | Needham, MA | 00 | 00000 | 000000000 | 00000 |
000000 | Formerly VC-backed | Bothell, WA | 0000 | 00.000 | 000000&0 | 00.000 |
INHIBITOR Therapeutics Patents
INHIBITOR Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20190365742-A1 | Azole treatment regimen with reduced hepatotoxicity | Inactive | 30-May-2018 | 0000000000 |
INHIBITOR Therapeutics Executive Team (3)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Garrison Hasara | Chief Financial Officer, Treasurer, Corporate Secretary, Chief Compliance Officer |
INHIBITOR Therapeutics Board Members (2)
Name | Representing | Role | Since |
---|---|---|---|
000000 0'00000 | INHIBITOR Therapeutics | Board Member | 000 0000 |
000000 00000 00. | INHIBITOR Therapeutics | Board Member | 000 0000 |
INHIBITOR Therapeutics Signals
INHIBITOR Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
INHIBITOR Therapeutics Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Commonwealth Biotechnologies | 09-Aug-2013 | 0000000000 | Other Healthcare Services |